It is well known that the fibrinolytic system actively participates in inflammatory processes. To investigate the role of the urokinase system in atopic allergy, we assessed circulating levels of urokinasetype plasminogen activator (uPA) and its soluble receptor (suPAR) in patients with pollen allergy suffering from allergic rhinitis and asthma during a period of natural pollens exposure. Plasma concentrations of uPA and suPAR were measured in 19 patients sensitized to grass and rye pollens (12 men and 7 women, 18 to 30 years old) who had seasonal allergic rhinitis and concomitant seasonal asthma symptoms, and 23 age-and sex-matched healthy controls, using THE enzyme-linked immunosorbent assay (ELISA) method. There were no significant differences in plasma concentrations of uPA and suPAR between patients and the control subjects. Seasonal allergic airway inflammation is not associated with enhanced release of uPA and suPAR into the systemic circulation.
It is well known that components ofthe urokinase system including urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) are synthesised by circulating immune and inflammatory cells, including cells involved in allergic processes (1-2). There is increased evidence that the urokinase system is an important modulator of immune responses (3) . Interestingly, it has been suggested that mediators of the system may modulate dendritic cell-induced T-Iymphocyte activation (4) as well as T-Iymphocyte response (5) . It has been demonstrated that mice deficient in uPA have profoundly impaired immunity involving both Thl and Th2 polarization and are largely immunologically hyporesponsive and display characteristics of functional anergy, suggesting some role of the urokinase system in Tlymphocyte mediated disorders (5). The urokinase system has been reported to play an important role in inflammatory and immune reactions but its significance in allergy is poorly characterised. Previously, we demonstrated that plasma concentration of uPA and soluble form of uPA receptor (suPARlCD87) in atopic eczema/dermatitis syndrome (AEDS) patients (6) and allergic rhinitis patients (7) did not differ significantly as compared to healthy subjects. In the present study, we further investigated the behaviour of circulating mediators or the urokinase system in atopic allergy, because it is well known that similarities exist regarding the profile or inflammatory mediators and circulating cell activity between various atopic diseases such as asthma, rhinitis, conjunctivitis, or AEDS, but there are also some differences. Therefore, we assessed plasma concentrations of uPA and suPAR in patients sensitized to grass-and rye-pollen allergens suffering from untreated seasonal allergic rhinitis and concomitant seasonal asthma during the pollen season.
MATERIALS AND METHODS
The study group consisted of nineteen non-smoking patients with diagnosis of allergy to grass and rye pollens who were suffering from untreated seasonal allergic rhinitis with concomitant asthma symptoms during the pollen season. Their clinical characteristics are shown in Table I . All patients had symptoms of allergic rhinitis and seasonal asthma at the time of the investigation and were studied during a period of natural grass and rye pollen exposure. The control group consisted of twenty-three non-atopic healthy subjects (15 male and 8 female, the median age was 22 years. range: 18-30) with no signs of atopy.
The Local Ethics Commission approved this study and written informed consent was obtained from all participating subjects.
Blood sampling and plasma preparation
Blood samples were taken in the morning (7.00 to 8.00; in the fasting state) from the antecubital vain directly into plastic tubes with EDTA as anticoagulant. The plasma was separated by centrifugation for 20 minutes at 2000g and 4°C. All samples were immediately frozen and stored at -70°C until analysis.
Assay ofu-Prl antigen
Measurement of u-PA antigen in plasma was carried out by specific ELISA according to the manufacture's recommendations (Irnubind ELISA kits, American Diagnostica lnc., Greenwich, CT, USA).
Soluble uPAR assay
Soluble uPAR 111 plasma was measured by a quantitative ELISA kit (R&D, Minneapolis. USA) according to the manufacture's instructions.
Skin prick tests
Allergic status was evaluated by skin prick testing with a panel of common inhalant allergens (grass, weed and tree pollens, cat and dog dander, moulds, house dust mite species) (Allergopharma, Reinbek, Germany), A wheal with a diameter at least 3 mm greater than the negative control was taken as a positive response.
Statistical analysis
Data are presented as medians, range. means. standard deviation (SD). Comparisons between groups were performed by Mann-Whitney's test. P values lower than 0.05 were considered significant.
RESULTS
There were no significant differences in plasma concentrations of uPA and suPAR between patients suffering from both seasonal allergic rhinitis and asthma and the controls (Table II) .
DISCUSSION
Atopic dermatitis, allergic rhinitis and asthma are atopic diseases that develop on a complex genetic background, the so-called atopic diathesis (8) . It has been suggested that atopy and haemostasis are linked. Both local and systemic changes in behaviour of components of the haemostatic system have been demonstrated in patients with atopic allergy (9). However, data regarding the function of fibrinolytic system, in particular the urokinase system in these diseases is limited. uPA and uPAR were shown to be active during a severe ocular allergic inflammation, and to be expressed by conjunctival tissues and inflammatory cells (10). Moreover, expression of uPA was significantly higher in allergic nasal mucosa in comparison with normal nasal tissues. It seems that uPA activity may help the passage of large amounts of rhinorrhea in allergic rhinitis ( 11). In addition, it has been suggested that the fibrinolytic system play an active role in airway remodeling in asthma (12) (13) . Increased cutaneous and plasma activity of the fibrinolytic system was observed during exacerbation of AEDS, suggesting a role of the system in amplification of inflammatory phenomenon in the disease (14) . Moreover, we have previously reported on enhanced platelet activation but normal D-dimer level in the systemic circulation of patients suffering from seasonal allergic rhinitis and asthma symptoms (15) (16) . Banach-Wawrzenczyk et al. (17) observed increased levels of tissue-type plasminogen and other fibrinolytic markers in peripheral blood of symptomatic patients with newly recognised asthma, suggesting that the activity of fibrinolysis system is increased in asthmatic subjects (17) . However, in this study plasma concentration of uPA in asthmatics was significantly lower when compared with healthy subjects, suggesting that uPA does not play an important role in the pathogenesis of bronchial asthma (17) . In contrast, in our study, we did not show significant differences in plasma concentration of uPA between untreated patients with both seasonal allergic rhinitis and asthma and healthy controls. Moreover, normal plasma concentration of uPA was reported in patients with severe form of allergic conjunctivitis such as vernal keratoconjunctivitis (10).
As mentioned above, up-regulate uPAR expression and release of soluble uPAR may accompany immune and inflammatory processes. There are no available data regarding circulating levels of soluble receptor for uPAR in patients with asthma nor for allergic rhinitis. As mentioned above, we previously reported that plasma concentration of suPAR in AEDS patients did not differ significantly when compared with healthy subjects.
In conclusion, we failed to detect significant differences in plasma levels of uPA and suPAR between the patient group and the healthy controls. It seems that circulating levels of uPA and suPAR are not changed in patients with pollen allergy suffering from seasonal allergic rhinitis and concomitant seasonal asthma symptoms. We can speculate that inflammatory events, which occur during IgE-mediated processes associated with seasonal allergic rhinitis and seasonal asthma, do not lead to enhanced release of uPA and suPAR into the systemic circulation. Even though an enhanced release of uPA and suPAR in the systemic circulation could not be detected, a uPA-dependent plasminogen activation system role in the pathogenesis of allergy could not be excluded. In fact, uPA and/or uPAR increased expression and activation in affected tissues could be important, as shown in vernal keratoconjunctivitis (10).
